ALESSANDRO GONCALVES CAMPOLINA
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina - Líder
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina - Líder
22 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 22
conferenceObject UTILIZATION OF PROPENSITY SCORE IN COMPARISON OF TWO THERAPEUTIC OPTIONS IN PATIENTS WITH SQUAMOUS CELL CARCINOMA OF HEAD AND NECK, BRAZIL 1998-2008(2015) CAMPOLINA, A. G.; COSTA, A.; V, R. LopezconferenceObject SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS IN CANCEROLOGY IN BRAZIL BETWEEN 1980 AND 2013(2014) YUBA, T. Y.; DECIMONI, T. C.; LEANDRO, R.; CAMPOLINA, A. G.; SOAREZ, P.conferenceObject ECONOMIC ANALYSIS OF HEPATO CELLULAR CARCINOMA TREATMENT BY SEVERITY OF DISEASE(2017) TANI, J. A.; CAMPOLINA, A. G.; DECIMONI, T. C.; TOMITAO, M.; FERREIRA, L. A.conferenceObject COMPARISON OF TREATMENTS FOR CANCER OF HEAD AND NECK ADJUSTED BY INCLINATION SCORE: RADIOTHERAPY VERSUS SURGERY plus RADIOTHERAPY(2015) CAMPOLINA, A. G.; COSTA, A.; LEANDRO, R. F.; V, R. Lopez; SOAREZ, P. C.conferenceObject EVALUATION OF AN INTEGRATED CARE PATHWAY FOR RECTAL CANCER TREATMENT IMPLEMENTATION USING A LOGIC MODEL(2016) KOBAYASHI, S. T.; CAMPOLINA, A. G.; SOAREZ, P. C.; JR, U. Ribeiro; DIZ, M. D.; HOFF, P. M.conferenceObject COST-EFFECTIVENESS ANALYSIS OF ON-PUMP AND OFF-PUMP STABLE MULTIVESSEL CORONARY ARTERY BYPASS GRAFTINGA angstrom MASS III 5-YEAR FOLLOW-UP(2016) SCUDELER, T. L.; HUEB, W.; SOAREZ, P. C. de; CAMPOLINA, A. G.; HUEB, A. C.; REZENDE, P. C.; LIMA, E. G.; GARZILLO, C. L.; COSTA, L. M.; OIKAWA, F. T.; RAMIRES, J. A.; KALIL FILHO, R.- Integration of the palliative care team with oncologic care in a tertiary cancer center in Brazil: Perception of patients and healthcare professionals after 1 year of integration(2020) GUIMARAES, T. V.; CAMPOLINA, A. G.; COSTA, F. N.; SPONTON, M. H. C.; DIZ, M. D. P. E.; SILVA, M. R.; CHIBA, T.
conferenceObject Impact of Early Referral for Palliative Care in the Use of Emergency Care for Patients with Advanced Cancer(2017) ROZMAN, L. M.; CAMPOLINA, A. G.; V, R. Lopez; CHIBA, T.; SOAREZ, P. C. De- Multiple Criteria Decision Analysis (MCDA) for evaluating cancer treatments in hospitalbased health technology assessment: The Paraconsistent Value Framework(2022) CAMPOLINA, A. G.; ESTEVEZ-DIZ, M. Del Pilar; ABE, J. M.; SOáREZ, P. C. deBackground In recent years, the potential of multi-criteria decision analysis (MCDA) in the health field has been discussed widely. However, most MCDA methodologies have given little attention to the aggregation of different stakeholder individual perspectives. Objective To illustrate how a paraconsistent theory-based MCDA reusable framework, designed to aid hospital-based Health Technology Assessment (HTA), could be used to aggregate individual expert perspectives when valuing cancer treatments. Methods An MCDA methodological process was adopted based on paraconsistent theory and following ISPOR recommended steps in conducting an MCDA study. A proof-of-concept exercise focusing on identifying and assessing the global value of first-line treatments for metastatic colorectal cancer (mCRC) was conducted to foster the development of the MCDA framework. Results On consultation with hospital-based HTA committee members, 11 perspectives were considered in an expert panel: medical oncology, oncologic surgery, radiotherapy, palliative care, pharmacist, health economist, epidemiologist, public health expert, health media expert, pharmaceutical industry, and patient advocate. The highest weights were assigned to the criteria ""overall survival""(mean 0.22), ""burden of disease""(mean 0.21) and ""adverse events""(mean 0.20), and the lowest weights were given to ""progression-free survival""and ""cost of treatment""(mean 0.18 for both). FOLFIRI and mFlox scored the highest global value score of 0.75, followed by mFOLFOX6 with a global value score of 0.71. mIFL was ranked last with a global value score of 0.62. The paraconsistent analysis (para-analysis) of 6 first-line treatments for mCRC indicated that FOLFIRI and mFlox were the appropriate options for reimbursement in the context of this study. Conclusion The Paraconsistent Value Framework is proposed as a step beyond the current MCDA practices, in order to improve means of dealing with individual expert perspectives in hospital- based HTA of cancer treatments. © 2022 Campolina et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
conferenceObject HEALTHCARE UTILIZATION AND SURVIVAL ASSOCIATED WITH CLINICAL CARE PATHWAY FOR RECTAL CANCER TREATMENT(2017) CAMPOLINA, A. G.; KOBAYASHI, S. T.; SOAREZ, P. C.; DIZ, M. D.
- «
- 1 (current)
- 2
- 3
- »